Analytical Data
-
基因名
CD276
- Application
-
别名
B7-H3; B7H3; CD276 Molecule; B7 homolog 3; Costimulatory molecule
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q5ZPR3
-
表达区间
Thr47~Ser219
-
分子量
22kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD276, also known as B7-H3, is a member of the B7 family of immune checkpoint molecules that plays a critical role in modulating immune responses. Initially identified as a glycoprotein expressed on the surface of various immune and non-immune cells, CD276 has garnered significant attention due to its involvement in tumor immune evasion, making it a potential target for cancer immunotherapy. Elevated levels of CD276 are associated with poor prognosis in several malignancies, including melanoma, lung cancer, and prostate cancer, as it promotes T-cell suppression and inhibits anti-tumor immunity. The development of recombinant CD276 protein has facilitated research into its structure, function, and interactions with other immune checkpoints. This protein serves as a valuable tool for elucidating the mechanisms by which CD276 influences immune responses, and for evaluating its potential as a therapeutic target. Furthermore, recombinant CD276 is being investigated for its capacity to generate monoclonal antibodies and other therapeutic agents aimed at enhancing anti-tumor immunity. Understanding the role of CD276 in the immune microenvironment and its functional implications could pave the way for novel immunotherapeutic approaches in oncology.
